Maria S. Viana

Ms. Maria S. Viana

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2023 in Catalysts
Verified
Journal Article
Open access
PDF file
MVMaria S. Viana
Maria S. Viana
Clara GomesClara Gomes
Clara Gomes
VRVitor Rosa
Vitor Rosa
A series of nine cationic heteroleptic aryl-BIAN-copper(I) (BIAN = bis-iminoacenaphthene) complexes with the general formula [Cu((E-C6H4)2BIAN)(PPh3)2][X] (E = p-Me, p-iPr, o-iPr; X = BF4, OTf, NO3) 1X–3X were synthesized and fully characterized using several analytical techniques, including NMR spectroscopy and single-crystal X-ray diffraction. Except for complexes 2BF4 and 3BF4, which were already reported in our previous works, all remaining complexes are herein described for the first time. Two different strategies were used for the preparation of the complexes: complexes bearing BF4− or OTf− counter-ions (1BF4, 1OTf, 2OTf, and 3OTf) were obtained using the appropriate copper(I) precursors [Cu(NCMe)4][BF4] or [Cu(NCMe)4][OTf], whereas for derivatives 1NO3–3NO3, [Cu(PPh3)2NO3] was used. Their activity as catalysts for the copper azide-alkyne cycloaddition (CuAAC) was assessed alongside other high activity, previously reported Cu(I) complexes. Comparative studies to determine the influence of the counter-ion and of the aryl substituents were performed. All complexes behaved as active catalysts under neat reaction conditions, at 25 °C and in short reaction times without requiring the use of any additive, with complex 2NO3 being the most efficient derivative, along with other NO3−-bearing complexes.

26 July 2026 in ChemMedChem
Verified
Journal Article
Open access
PDF file
MMM. Margarida Martins
M. Margarida Martins
RVRuben Valente
Ruben Valente
RARuben Amaro
Ruben Amaro
MVMaria S. Viana
Maria S. Viana
RJRita de Jesus
Rita de Jesus
Luisa FerreiraLuisa Ferreira
Luisa Ferreira
The development of new therapeutic agents for glioblastoma and hepatocellular carcinoma (HCC) remains a priority due to poor prognosis, limited treatment options, and high recurrence rates. Herein, we report a one‐pot synthesis of aromatic aminopropyl lactams (ArAPLs) via hydrolysis of bicyclic amidines (DBN, DBU), followed by reductive amination with aromatic aldehydes. These compounds were designed to target histamine H 3 receptors (H 3 R), which are often overexpressed in these malignancies. Docking studies suggested that compounds 3a and 4a may act as H 3 R antagonists, showing favorable binding through hydrophobic and hydrogen‐bonding interactions. Biological evaluation identified 3a and 4a as the most promising compounds, exhibiting micromolar antiproliferative activity in glioblastoma and HCC cell models. Compound 3a showed the best balance between potency and selectivity, including activity in 3D spheroid models and modulation of cell cycle‐related markers. In coculture systems, spheroids displayed reduced size and density, although a slight increase in viability was observed, particularly with 4a . Variations in peripheral cell layers suggest a role for macrophage behavior. Overall, these findings support the cytotoxic potential of ArAPLs, although further studies are required to confirm their role as H 3 R antagonists.